RadLink Asia’s Singapore Radiopharmaceuticals Becomes The Exclusive Manufacturer And Supplier Of Vizamyl Molecular Imaging Agent On Behalf Of GE Healthcare In Singapore

RadLink Asia’s Singapore Radiopharmaceuticals Becomes The Exclusive Manufacturer And Supplier Of Vizamyl Molecular Imaging Agent On Behalf Of GE Healthcare In Singapore

  • The agreement demonstrates RadLink Asia and Fullerton Health’s commitment to improving the quality of care delivered while increasing accessibility and affordability for its patients
  • This transfer of technology from GE Healthcare is also a testament of RadLink’s leadership in Singapore’s radiopharmaceutical and molecular imaging sector

Singapore, 07 September 2018 — Following General Electric (“GE”) Healthcare’s attainment of the license and regulatory approval of VIZAMYL in Singapore, RadLink Asia (“Radlink”), a wholly-owned subsidiary of Fullerton Health, announces today that its radiopharmaceutical unit, Singapore Radiopharmaceuticals Pte Ltd (“SRP”), is the exclusive manufacturer and supplier of VIZAMYL in Singapore on behalf of GE Healthcare.

VIZAMYL is the first-and-only beta-amyloid imaging agent for colour image interpretation approved by the U.S. Food and Drug Administration (“FDA”) and the European Medicines Agency (“EMA”). It can effectively detect beta-amyloid plaques in patients being evaluated for cognitive disorders, including Alzheimer’s disease (“AD”), offering the prospect of earlier diagnosis for such patients.

Following a successful technology transfer of VIZAMYL from GE Healthcare to SRP and a thorough audit of the latter’s facilities and manufacturing standards, the parties signed an agreement that will enable SRP to manufacture and supply VIZAMYL for the Singapore market. This is a significant milestone which firmly demonstrates RadLink’s commitment to invest in innovative healthcare technologies and further cements the company’s leadership position in Singapore’s molecular imaging sector.

“The availability of VIZAMYL in Singapore is a step ahead for the local medical community as it allows physicians to provide better care to their patients. This is a vision that we are proud to share with RadLink and other Singapore radiopharmaceutical companies,” said Ms. Myra Eskes, President & CEO, GE Healthcare ASEAN, Korea and ANZ. “Advancements to medical imaging through agents such as VIZAMYL can help open up treatment options by helping physicians identify the most suitable people for the right clinical trials, potentially leading to medications to deal with Alzheimer’s.”

Commenting on the agreement, Mr. Royston Lek, Regional Managing Director of RadLink, said, “Across Asia, there has been a dramatic increase in demand for better imaging and diagnostics, fuelled by an aging population and increasing prevalence of chronic diseases. Against this backdrop, we have been constantly introducing new technologies and enhancing our expertise to deliver the best quality of care to our patients. We are proud to partner with GE Healthcare, working together to raise standards in molecular imaging and better assist clinicians in the diagnosis and treatment of diseases like Alzheimer’s.”

VIZAMYL will be manufactured by SRP at its facility located at Science Park II in Singapore.

About RadLink Asia

RadLink Asia, a wholly-owned subsidiary of Fullerton Health, is Singapore’s largest private provider of diagnostic imaging, molecular imaging and teleradiology services. RadLink’s diagnostic imaging services include X-ray, Ultrasound, Mammography, Fluoroscopy, Bone Mineral Densitometry, Magnetic Resonance

Imaging (“MRI”) and Computed Tomography (“CT”) scans. RadLink also provides molecular imaging and services such as Positron Emission Tomography (“PET”) and radionuclide therapy for oncology, heart and bone diseases. Through its Medisol subsidiary, Radlink also provides teleradiology services to more than 30 independent, third-party imaging centres, medical groups and hospitals.

RadLink operates out of their flagship centers, RadLink Diagnostic Imaging Centre and RadLink PET Centre, in Paragon Medical, located in the heart of Singapore’s medical tourism hub along Orchard Road, as well as six other satellite medical centers. In addition, RadLink’s radiopharmaceuticals facility in Science Park provides the most comprehensive set of tracers to physicians and hospitals throughout Singapore and has established new tracers used in preclinical research to investigate disease biomarkers.

For more information on RadLink Asia, please visit http://www.radlink.com.sg/.

About Fullerton Health

Fullerton Health is a leading vertically integrated healthcare platform in the Asia Pacific region. Founded in Singapore in 2011, today they serve clients through over 500 healthcare facilities and a large global network of healthcare providers across eight markets in Asia. Fullerton Health’s value proposition is the integration of healthcare service offerings with customized management and advisory capabilities, in line with its mission to transform Asian healthcare and make it affordable and accessible for enterprise clients.

For more information on Fullerton Health, please visit http://www.fullertonhealth.com/.

About GE Healthcare

GE Healthcare is a leading provider of medical imaging, monitoring, biomanufacturing, and cell and gene therapy technologies. GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services. With over 100 years of experience and leadership in the healthcare industry and more than 50,000 employees globally, GE Healthcare helps healthcare providers, researchers and life sciences companies in their mission to improve outcomes for patients around the world. Follow us on Facebook, LinkedIn, Twitter and The Pulse for latest news, or visit our website www.gehealthcare.com for more information.

Media contact
Brunswick Group
Will Carnwath, Ben Fry
FullertonHealth@brunswickgroup.com
+65 6426 8188


GE Healthcare
Denise Nah
Denise.nah@ge.com
+65 9832 9936

MRI Breast Course with MRI Guided biopsy workshop

MRI Breast Course with MRI Guided biopsy workshop

Venue: Holiday Inn Singapore Orchard City Centre
Date: 15-16 December 2018
Time: 8:00 am to 6:00 pm

Course Director: Dr Niketa Chotai. Consultant, RadLink Diagnostic Imaging Centre, Visiting Consultant, TTSH.

International faculty: Dr Supriya Kulkarni, Assistant Professor, University of Toronto. Director of Breast Imaging Education and Fellowships. Staff Radiologist, Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Woman’s College Hospital.

Overview:

This is a two days course during which the participants will be exposed to intensive training on basics of MRI Breast technique, MRI breast guidelines, Hands-on reading MRI breast. There will be lectures, extensive workstations based case reviews and Question answer sessions. There will be exposure to average 60 MRI Breast cases. There will be half day hands-on workshop on MRI Guided Breast biopsy.

Objective of the course:
At the end of the course the participants will be able to:

  • Describe various indications and guidelines for Breast MRI. They will know pros and cons of using this modality in various clinical conditions.
  • Report MRI Breast study systematically with utilization of appropriate BI-RADS Lexcion as described by ACR Guidelines.
  • Have enhanced interpretative skills of reading Breast MRI in various breast conditions, including breast implants
  • Use various protocols with understanding of usefulness of each sequence.
  • Learn safe and effective MRI guided breast biopsy technique

Sign up before 31 July 2018 to enjoy early bird rates! Register NOW

Overcoming Mammogram Fears Together – A Singaporean Family’s Experience

Overcoming Mammogram Fears Together – A Singaporean Family’s Experience

Oct 6, 2017 by GE Reports Staff

While Singapore is third in the world for life expectancy according to the latest World Health Statistics report by the World Health Organization (WHO), breast cancer for women, and prostate cancer for men, has increased significantly over the past 40 years.

As reported in the June 21, 2017 issue of Singapore’s Straits Times newspaper, breast cancer has more than doubled from 25 to 65 per 100,000 women since 1977. And between 2011-215, 2,105 women died of breast cancer – more than half of the women diagnosed were aged between 45 and 65.

Of these women, 71 per cent were diagnosed in the early stages which gives them a higher chance of survival. Stage one patients have a 91 per cent chance of surviving more than five years. Based on these statistics and findings, local health authorities want more women to have regular breast screenings.

It is a challenge however, as only 40 per cent of older women have received a breast cancer screening in the past two years according to research conducted by the Singapore Health Promotion Board. This is an important trend to address because the risk of breast cancer increases with age.

Although the best chance of early detection of breast cancer is through a mammogram, many women avoid regular scans due to fear and anxiety of potential findings, and exam discomfort.

Overcoming fears together – a family experience

Above from left: Nancy Yang-Goh (aged 71) and her daughters – both first time mammogram-goers – Veronica Yang (aged 39) and Mary Stevenson-Yang (aged 41). To better understand why Singaporean women are reluctant to have regular scans, GE Healthcare and RadLink Asia, one of Singapore’s largest private providers of outpatient diagnostic and molecular imaging services, recently interviewed Nancy Yang-Goh, aged 71, and her daughters, Mary Stevenson Yang (aged 41), and Veronica Yang (aged 39) who had a mammogram scan together at the RadLink Diagnostic and Imaging Center in “Singapore.”

They spoke about their experience around making breast cancer awareness a family discussion, and whether their pre-scan perceptions, fears, or anxieties, were real or imagined.

Nancy shared “I was really fearful. When I saw the machine I thought to myself, my goodness what are you going to do to me, with this machine?” But after I went through the experience, I thought it was okay. It is not painful and there was nothing to be scared of.”

Eldest daughter Mary had two primary concerns, “The first being the pain. I heard from friends that it can be uncomfortable and painful. The second was the radiation because I heard that the radiation can affect other organs of the body, like the thyroid.”

She added, “I used to think that a regular mammogram scan was not important but having done my first recently, it got me thinking that this is a good way to take care of myself and seeing the results put my mind at ease that everything is okay.”

Mary’s view was echoed by her sister, Veronica.

She said, “A regular mammogram is something that I would schedule even though I’m starting early – there is no time like the present.”

Putting the findings to use

Commenting on the what by Mrs. Yang-Goh and her daughters shared, Dr. Niketa Chotai, Consultant Radiologist, RadLink Diagnostic Imaging Center said, “In my experience as a radiologist, and as a woman myself, I know that mammography is a very personal topic that could evoke all kinds of emotions from fear, anger or perhaps even, indifference. By asking women of different age groups to speak on their
experience, we want all females to consider the fact that breast cancer screening is relevant to any woman, regardless of her age.

“And with filial piety being a big part of Asian culture, we also wanted to encourage women to consider doing this as an annual family activity as a way ease into this habit when she reaches 40 – the recommended age to start going for a mammogram.”

Dr. Chotai said as the interview findings were insightful and enlightening, and more interviews with more families, may be considered in the future, with the key messages to be used in possible upcoming mammogram awareness and communication programs.

RADLINK ASIA UNVEILS UPGRADED FACILITY FEATURING NEW FULLY-DIGITAL, PET/CT SCANNER

RADLINK ASIA UNVEILS UPGRADED FACILITY FEATURING NEW FULLY-DIGITAL, PET/CT SCANNER

Singapore, 17th August 2017 — RadLink Asia announced that the company’s Molecular Imaging unit, RadLink PET and Cardiac Imaging Centre (“RadLink”), has today unveiled its updated flagship clinic in Paragon Medical Centre. The newly upgraded facility doubles the number of patient rooms and features Southeast Asia’s fully-digital Positron Emission Tomography (“PET”)/Computed Tomography (“CT”) scanner. The new scanner, which is available for use immediately, uses technology that detects smaller1, assisting clinicians in their efforts to diagnose and stage disease. Additionally, radio-isotope doses and scan times are significantly reduced2, hence improving the overall patient experience.

“We are proud to partner with Radlink-Asia in its vision to be a leading provider of diagnostic and molecular imaging in Singapore. The fully digital PET/CT system from GE has the potential to reshape the future of oncology diagnosis, staging and treatment planning with technology that can detect small lesions,” said Myra Eskes, President & CEO, GE Healthcare ASEAN.

The new system brings together the sensitivity of digital detection with innovative reconstruction technology available, combining Time-of-Flight and a PET image reconstruction technology to ensure consistent and accurate Standard Uptake Values (“SUV”) measurements.

This delivers up to a 2-fold improvement in PET quantitation accuracy (SUVmean), and double improvement in image quality3 . With more accurate SUVs, clinicians will be able to more accurately assess treatment response and guide treatment planning decisions as well as conduct research such as quantitative brain studies, boosted by an expanded field-of-view.

The technology has the potential to increase clinicians’ diagnostic service offerings by enabling clinical excellence in oncology and pushing the boundaries of PET user technology in neurology, cardiology and beyond. These expanded capabilities are made possible by increased low-yield tracer capability with protocols that could reduce radiation dosages; allowing clinicians to pursue ground-breaking research without impacting image quality.

Gwendolene Yeo, Managing Director for RadLink Asia commented, “As cancer incidence rates climb across Singapore and the region, and as treatment options become more personalized with precision medicine, it is only natural that Fullerton invests further in RadLink’s molecular imaging business in assisting clinicians to diagnose, stage and treat cancers earlier. Our investment in the new digital PET/CT scanner enacts our mission in raising healthcare standard. We want patients to receive quality care in a more accessible and affordable manner.”

The new fully digital PET/CT scanner has commenced operations at RadLink PET and Cardiac Imaging Centre, located at Paragon Medical Centre.

1 Improved detectability as demonstrated in phantom testing.

2 Compared to Discovery PET/CT 710

3 Improved detectability as demonstrated in phantom testing.

About RadLink Asia

RadLink Asia, a wholly-owned subsidiary of Fullerton Health, is one of Singapore’s largest private provider of outpatient diagnostic and molecular imaging services. RadLink’s diagnostic imaging services include X-ray, Ultrasound, Mammography, Fluoroscopy, Bone Mineral Densitometry, Magnetic Resonance Imaging and Computed Tomography scans. RadLink also provides molecular imaging and services such as Positron Emission Tomography and radionuclide therapy for oncology and bone diseases.

RadLink operates out of their flagship centers, RadLink Diagnostic Imaging Centre and RadLink PET and Cardiac Imaging Centre, in Paragon Medical, located in the heart of Singapore’s medical tourism hub along Orchard Road, as well as six other satellite medical centers offering general radiology services. In addition, RadLink’s radiopharmaceuticals facility in Science Park provides the most comprehensive set of tracers to physicians and hospitals throughout Singapore and has established new tracers used in preclinical research to investigate disease biomarkers.

For more information on RadLink Asia, please visit http://www.radlink.com.sg/

About Fullerton Health
Fullerton Health is a leading provider of corporate healthcare solutions across Asia Pacific. Founded in Singapore in 2011, today we own more than 225 medical centres across 6 countries and have a network of more than 8,000 medical providers around the world. We harness these resources to provide you healthcare that is affordable, yet accessible.

More than 25,000 corporations, from multinational companies to small medium enterprises and government organisations, have chosen to use our services. Our integrated healthcare model and our scale mean we can offer one-stop, cost-effective solutions to our corporate and insurer clients, and better care to our patients.

What’s more, we are strong believers in innovation, and in staying ahead of technological developments. This means we have our own advanced technology system that powers the Fullerton network, and enables this network to grow further. This gives us a continuing ability to improve business performance and efficiency, which in turn creates cost-savings for our customers.

With 50 years of experience listening and caring, and an experienced management team that brings the best from different industries, we are now better poised to transform healthcare in Asia, making it affordable and accessible to those we serve.

For more information on Fullerton Health, please visit http://www.fullertonhealth.com/

About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE Healthcare (NYSE: GE) works on things that matter – great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions GE Healthcare helps medical professionals deliver great healthcare to their patients. http://www.gehealthcare.com

Media contact:
Brunswick Group
Will Carnwath, Ben Fry
FULLERTONHEALTH@brunswickgroup.com

GE Healthcare
Denise Nah
Denise.nah@ge.com
+65 9832 9936

Discovery™ MI – ASEAN’s First Fully-Digital PET/CT Scanner

Discovery™ MI – ASEAN’s First Fully-Digital PET/CT Scanner

The newly installed PET/CT in RadLink PET Centre is empowered by a fully digital technology engineered for precision, designed to help diagnose and stage disease earlier and hence better guide your treatment strategies.

Discovery™ MI is the only PET/Ct that brings together the sensitivityof digital detection with the most innovative reconstruction technology available, the combination of Time-of-Flight and Q.Clear. In addition to advancements in reconstruction and detection technology, Discovery™ MI includes diagnostic CT innovations with the Clarity Imaging System, innovative ASIR-V™ iterative reconstruction method and and 5martMAR Virtually eliminating streaks and shadows caused from metal artifacts – resulting in:

Outstanding resolution to improve the detection of small lesions

Up to 82 percent dose reduction at the same image quality in routine imaging across applications

2x increase in spatial resolution

Enhance utilization of limited-access tracers, such as Ga, with highest NEMA sensitivity of any TOF PET/CT

Half the time or half the dose in PET imaging

Provide a more comfortable patient experience with short scan times

SMALL LESION DETECTABILITY

Conventional PET Detection

Patient with history of melamona referred to PET/CT for re-staging and metastatic evaluation.

Smaller lesion detection through digital PET

Discovery™ MI provides more confidence when looking for small metatastic disease in difficult arwa such as the liver.

The exclusive innovative PET image reconstruction technology. Q.Clear and Q.SUV ensure consistent and accurate SUV measurements than conventional methods which delivers not only up to a 2x improvement in PET quantitaion accuracy [SUVmean], but also up to a 2x improvement in image quality. With accurate SUVs, it means more accurately assess treatment response to guide your treatment planning decisions.

1/2 Time, No Compromise

Full Acquisition time 12 min

SUVmax: 7.45 Liver
SUVmean: 20.07

1/2 Acquisition time 6 min

SUVmax: 7.53 Liver
SUVmean: 20.01

Flutemetamol F18 Injection – For early onset of Alzheimer PET scan

Flutemetamol F18 Injection – For early onset of Alzheimer PET scan

The First-and-Only Amyloid Imaging Agent with FDA Approval for Color Image Interpretation

Flutemetamol F18 Injection color images provided accurate amyloid detection

In Study 1:
Hign median sentivity and specificity in autopsy standard-of-truth assesment among five independent, blinded image readers.

In Study 2:

  • Flutemetamol F18 Injection color image reads demonstrated high inter-reader agreement for visual image interpretation (kappa score 0.83, 95% CI [0.79-086]).
  • An intra-reader reproducibility analysis involving two readings for each of 29 duplicate patient images showed: One of the five readers ahd complete agreement for all 29 images, two readers had discordant reads for a single image, and two readers had discordant reads for two images.
  • Intra-reader reproducibility for a subgroup of eight images from aMCI patients showed: All five readers had complete agreement for all duplicate images.
*AMCI – Amnestic Mild Cognitive Impairment

DISCOVER AMYLOID IMAGING IN COLOR

  • A negative Flutemetamol F18 Injection scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of Alzheimer’s disease at the point of image acquisition
  • A positive Flutemetamol F18 Injection scan indicates moderate to frequent amyloid neuritic plaques
  • Flutemetamol F18 Injection is an adjunct to other diagnostic evaluates

APPROPRIATE SITUATIONS FOR AMYLOID IMAGING

  • With persistent or progressive unexplained MCI
  • Who satisty core clinical criteria for possible Alzheimer’s disease because pf unclear clinical presentation, either a typical clinical course or an etiologically mixed presentation
  • With progressive dementia and a typically early age of onset (usually defined as < 65)

SAFETY OF FLUTEMETAMOL F18 INJECTION

In clinical trials of 761 patients dosed, one experienced a serious hypersensitivity reaction.

  • This reaction was accompanied by flushing, dyspnea, and chest pressure
  • The reaction occured within minutes of administration of Flutemetamol F18 Injection, and the patient recovered with treatment
  • The most commonly reported adverse reactions occured at a rate of <2% and were of mild to moderate intensity
  • The recommended dose is 185 MBq (5 mCi) injected intravenously. The adult effective dose is 5.92 mSv

Revolution CT – the first in Singapore

Revolution CT – the first in Singapore

The “First” Revolution CT in Singapore

First to be launched in Singapore, the high performance GE Revolution CT enhances patient safety and comfort through lower radiation and faster scanning time. Through its high-definition image quality and performance, patients rely less on beta blockers and other contrast agents, enabling a stress-free and comfortable scanning procedure.

Key Differentiators

QUALITY

Images that provide for a confident diagnosis

  • High spatial resolution
  • Low contrast detectability
  • Whisper Drive system to reduce audible noise

COVERAGE

Wide, flexible anatomical coverage

  • Complete organ coverage (160mm)
  • Simple, multi- phase exams
  • Quick answers
  • Temporal resolution (0.28s rotation speed)

SPEED

Fast acquisitions to avoid artifacts
related to motion

  • Gross movement
  • Respiratory motion
  • Pulsatile motion

TECHNOLOGY

Divergent technology solutions

  • 512 slices, whole organ coverage enables 4D imaging
  • High-D iterative reconstruction
  • Wider detector shuttle mode
  • Intelligent motion correction

A Revolution in cardiac CT

ONE BEAT, AT ANY HEART RATE

WHOLE HEART AXIAL IMAGING
MULTI-PHASE FOR HIGHER BPM

HIGH DEFINITION, LOW DOSE

18.2 LP/CM RESOLUTION

ASIR-V*1: REDUCE DOSE UP TO 82%

MOTION FREE WITH OR W/O BETA BLOCKERS

0.28 SEC ROTATION SPEED

SNAPSHOT* FREEZE

ARRHYTHMIA MANAGEMENT

MONITOR AND AVOID BAD BEATS, SCAN IN ONE BEAT

MULTIPLE EXAMS FROM JUST ONE BEAT

CORONARIES, STRESS PERFUSION & FUNCTION

PERSONALIZE 4D DYNAMIC IMAGING

WHOLE HEART PERFUSION & CTA WITHOUT TABLE MOTION

Signa Explorer – the first in S.E.A

Signa Explorer – the first in S.E.A

The “First” SIGNA Explorer MRI in South East Asia

First of its kind in ASEAN, the GE SIGNA Explorer MRI provides for maximum patient comfort through SilentScan; a noise reduction feature that scans at less than 3 decibels above ambient and enhanced motion-free imaging. Low quality images and long, uncomfortable scans will be a thing of the past with the SIGNA Explorer’s improved technology and clinical imaging capabilities.

Key Differentiators

ADVANCED APPLICATIONS

  • Scan faster and increased reconstruction capabilities
  • Scan without noise; completely silent brain exam

NEEDLE FREE APPLICATIONS

  • Non-invasive and minimally invasive scan techniques
  • Remove the need for contrast in many exams

MOTION FREE EXAMS

  • Reduced distortion due to patient motions
  • Allow free breathing
  • More consistent imaging quality & performance

ADVANCED APPLICATIONS

  • SILENT SCAN; reduces noise to less than 3 decibels above ambient
  • FOCUS; increasing resolution with single shot
  • MAVRIC SL: acquisition and reconstruction technique
  • Automated brain exam to simplify and improve throughput in neuro exams

Makeover of RadLink

Makeover of RadLink

Winner of Frost & Sullivan Company of the year award

Winner of Frost & Sullivan Company of the year award

WINNER OF FROST & SULLIVAN 2016 COMPANY OF THE YEAR (SINGAPORE DIAGNOSTIC IMAGING) AWARD

Presented to RadLink Asia for excellence in growth, innovation and leadership towards delivering significant contributions in the diagnostic imaging industry in Singapore.